10.96. C60H64O8N8 CH2Cl2 CH3CN requires C, 65.73; H, 6.04;
times. The solvent was evaporated to give cavitand 9 (340 mg,
N, 10.95%); νmax (KBr)/cmϪ1 1618 (C᎐N); δ (400 MHz, CDCl )
30%), mp 269.0 ЊC; νmax (KBr)/cmϪ1 1691.66 (N᎐N), 1626.09
᎐
᎐
H
3
1.00 (12H, m, CH2CH2CH3), 1.34 (8H, m, CH2CH2CH3), 2.21
(8H, m, CH2CH2CH3), 4.11 (4H, d, J 7.2, inner -OCH2O-), 4.76
(4H, m, ArCHAr), 4.87 (8H, s, ArCH2N), 5.91 (4H, d, J 7.2,
outer -OCH2O-), 6.89 (4H, d, J 7.0, imidazolyl-H5Ј), 7.02 (4H,
s, ArH), 7.20 (4H, d, J 7.2, imidazolyl-H4Ј), 7.40 (4H, s,
imidazolyl-H2Ј); FAB MS m/z 1025.27 (M + H+, 100%).
(C᎐N); δ (400 MHz, CDCl ) 1.01 (12H, m, CH CH CH ), 1.34
᎐
H 3 2 2 3
(8H, m, CH2CH2CH3), 2.22 (8H, m, CH2CH2CH3), 4.23 (4H, d,
J 7.4, inner -OCH2O-), 4.80 (4H, m, ArCHAr), 5.52 (8H, s,
ArCH2N), 5.54 (4H, d, J 7.4, outer -OCH2O-), 7.07 (4H, s,
ArH), 7.39–7.18 (8H, m, indazolyl-H), 7.47 (4H, d, J 8.5,
indazolyl-H), 7.72 (4H, d, J 7.2, indazolyl-H), 7.93 (4H, s,
indazolyl-H); FAB MS m/z 1225.4 (M+, 100%).
1,21,23,25-Tetrapentyl-7,11,25,28-tetrakis(imidazolylmethyl)-
2,20:3,19-dimethano-1H,21H,23H,25H-bis[1,3]dioxocino-
[5,4-i:5Ј,4Ј-iЈ]benzo[1,2-d:5,4-dЈ]bis[1,3]benzodioxocine (7b)
1,21,23,25-Tetrapropyl-7,11,25,28-tetrakis(benzimidazolyl-
methyl)-2,20:3,19-dimethano-1H,21H,23H,25H-bis[1,3]dioxo-
cino[5,4-i:5Ј,4Ј-iЈ]benzo[1,2-d:5,4-dЈ]bis[1,3]benzodioxocine (10)
Imidazole (5.72 g, 0.083 mol, 100 eq.) was dissolved in 50 mL of
CH3CN and stirred at rt for 30 min. Tetrakis(bromomethyl)cav-
itand 4b (1.00 g, 0.84 mM) was added and the mixture was
stirred for 3 h. The reaction mixture was concentrated, dis-
solved in CH2Cl2 and washed with basic water (3 M NaOH).
The organic phase was washed with deionized water several
times and the concentrated crude product was dissolved in
acetone, and the precipitate was filtered. The filtrate was
concentrated and the residue was recrystallized from a mixture
of CH2Cl2–CH3CN to give cavitand 7b (0.73 g, 77%), mp
207.0 ЊC (Found: C, 67.78; H, 7.01; N, 10.11. C68H80O8N8
CH2Cl2 CH3CN requires C, 67.50; H,6.78; N, 9.98%); νmax
(KBr)/cmϪ1 1610.66 (C᎐N); δ (400 MHz, CDCl3) 0.89 (12H,
m, (CH2)4CH3), 1.31 (24H, m, CH2(CH2)3CH3), 2.17 (8H, m,
CH2(CH2)3CH3), 4.07 (4H, d, J 7.03, inner-OCH2O-), 4.70 (4H,
m, ArCHAr), 4.85 (8H, s, ArCH2N), 5.88 (4H, d, J 7.03, outer
-OCH2O-), 6.87 (4H, d, J 7.0, imidazolyl-H5Ј), 6.99 (4H, d, J
7.4, imidazolyl-H4Ј), 7.16 (4H, s, ArH), 7.38 (4H, s, imidazolyl-
H2Ј); FAB MS m/z 1137.4 (M+, 100%).
Benzimidazole (11.2 g) was dissolved in 80 mL of CH3CN, and
stirred at 50 ЊC for 30 min. Tetrakis(bromomethyl)cavitand 4a
(1.0 g, 0.93 mmol) was added, and the mixture was stirred for
3 h. The solvent was evaporated, and benzimidazole was
washed out with MeOH. The precipitate was filtered, washed
with methanol several times to give cavitand 10 (89 mg, 78%) as
a white solid, mp >268.0 ЊC (decomp.); νmax (KBr)/cmϪ1 1608.73
(C᎐N); δ (400 MHz, CDCl3) 0.89 (12H, m, CH2CH2CH3),
1.22 (8H, m, CH2CH2CH3), 2.09 (8H, m, CH2CH2CH3), 4.10
(4H, d, J 5.1, inner -OCH2O-), 4.68 (4H, m, ArCHAr), 4.98
(8H, s, ArCH2N), 5.62 (4H, s, outer -OCH2O-), 7.15 (4H, s,
ArH), 7.24 (8H, m, benzimidazolyl-H), 7.48 (4H, d, J 7.8,
benzimidazolyl-H), 7.66 (4H, m, benzimidazolyl-H), 7.73 (4H,
s, benzimidazolyl-H); FAB MS m/z 1225.4 (M+, 100%).
᎐
H
᎐
H
7,11,15,28-Tetrakis(2-pyridylmethyl)-1,21,23,25-tetrapentyl-
2,20:3,19-dimethano-1H,21H,23H,25H-bis[1,3]dioxocino-
[5,4-i:5Ј,4Ј-iЈ]benzo[1,2-d:5,4-dЈ]bis[1,3]benzodioxocine
stereoisomer (11)
1,21,23,25-Tetrapropyl-7,11,25,28-tetrakis(pyrazolylmethyl)-
2,20:3,19-dimethano-1H,21H,23H,25H-bis[1,3]dioxocino-
[5,4-i:5Ј,4Ј-iЈ]benzo[1,2-d:5,4-dЈ]bis[1,3]benzodioxocine (8)
2-Picolyl chloride hydrochloride† (0.74 g) and tetraol 5 (0.20 g,
0.23 mmol) were dissolved in 30 mL of DMF, at 70 ЊC. The
mixture was stirred for 3 h and then 3 M HCl (30 mL) was
added. The mixture was extracted with CH2Cl2 and washed
with H2O, and then dried over MgSO4. The product was
crudely purified by silica gel gravity column chromatography
using 5% MeOH in CH2Cl2. The best fractions were collected
and washed with deionized water several times. The solution
was concentrated to give cavitand 12 (240 mg, 85%), mp
>215 ЊC (decomp.) (Found C, 71.89; H6.70; N, 4.85.
C76H84O12N4 H2O requires C, 72.24; H, 6.86; N, 4.43%); νmax
(KBr)/cmϪ1 1618.36 (C᎐N); δ (400 MHz, CDCl3) 0.90 (12H,
m, (CH2)4CH3), 1.35 (24H, m, CH2(CH2)3CH3), 2.19 (8H, m,
CH2(CH2)3CH3), 4.47 (4H, d, J 7.0, inner -OCH2O-), 4.72 (4H,
m, ArCHAr), 5.08 (8H, s, ArOCH2), 5.73 (4H, d, J 7.0, outer
-OCH2O-), 6.84 (4H, s, ArH), 7.18 (4H, t, J1 6.3, J2 6.11,
pyridinyl-H), 7.57 (4H, d, J 7.8, pyridinyl-H), 7.69 (4H, t, J 7.8,
pyridinyl-H), 8.52 (4H, d, J 4.2, pyridinyl-H); FAB MS m/z
1245.6 (M+, 100%).
Tetrakis(bromomethyl)cavitand 4a (0.50 g, 0.46 mmol) and
pyrazole (0.60 g) were dissolved in 50 mL of CH3CN with
K2CO3 (2.5 g) at 50 ЊC and the mixture was stirred for 3 h. The
mixture was concentrated, dissolved in CH2Cl2, washed with
water several times, and dried over MgSO4. The concentrated
crude product was purified by silica gel column chrom-
atography using EtOAc–hexane (2 : 1 to 5 : 1). The best
fractions were collected and concentrated. The residue was
dissolved in CH2Cl2 and washed with deionized water several
times. The organic phase was concentrated to give cavitand 8
(310 mg, 65%), mp 239 ЊC (Found: C, 69.05; H, 6.46; N, 10.47.
C60H64O8N8 H2O requires C, 69.08; H, 6.38; N, 10.74%);
νmax (KBr)/cmϪ1 1707.11 (N᎐N), 1637.67 (C᎐N); δ (400
᎐
H
᎐
᎐
H
MHz, CDCl3) 0.94 (12H, m, CH2CH2CH3), 1.30 (8H,
m, CH2CH2CH3), 2.10 (8H, m, CH2CH2CH3), 4.16 (4H, d,
J 7.4, inner -OCH2O-), 4.74 (4H, m, ArCHAr), 4.98 (8H, s,
ArCH2N), 5.70 (4H, d, J 7.4, outer -OCH2O-), 6.11 (4H, t,
J 2.0, pyrazolyl-H4Ј), 7.09 (4H, s, ArH), 7.31 (4H, d, J 2.1,
pyrazolyl-H5Ј), 7.34 (4H, d, J 0.8, pyrazolyl-H3Ј); FAB MS m/z
1025.48 (M+, 100%).
Tetrakis(p-imidazolylmethyl)-25,26,27,28-tetrahydroxycalix[4]-
arene 12
Tetrakis(chloromethyl)calix[4]arene 6 (100 mg, 0.16 mmol) was
dissolved in 2 mL of CHCl3, and stirred at Ϫ10 ЊC for 20 min.
Imidazole (720 mg, 10.5 mmol) was added, and the mixture was
stirred for 2 h. The reaction mixture was washed with basic
water (3 M NaOH) and then with deionized water. Undissolved
powder was filtered and washed with deionized water several
times to give cavitand 12 (60 mg, 50%), mp >170 ЊC (decomp.);
δ13C (100.4 MHz, DMF-d7) 33.30 (ArCH2Ar), 50.63 (ArCH2N),
120.01 (ArC), 127.07 (ArC), 127.92 (imidazolyl 5Ј-C), 128.89
(imidazolyl 4Ј-C), 131.61 (NCHN), 137.76 (ArC), 155.85
(ArCOH); δH (300 MHz, DMF-d7) 3.13 (4H, d, J 12.4, exo-
1,21,23,25-Tetrapropyl-7,11,25,28-tetrakis(indazolylmethyl)-
2,20:3,19-dimethano-1H,21H,23H,25H-bis[1,3]dioxocino-
[5,4-i:5Ј,4Ј-iЈ]benzo[1,2-d:5,4-dЈ]bis[1,3]benzodioxocine (9)
Tetrakis(bromomethyl)cavitand 4a (1.00 g, 0.93 mmol) and
indazole (2.2 g) were dissolved in 50 mL of CH3CN with K2CO3
(2.57 g). The mixture was refluxed for 24 h. The solvent was
evaporated, and the residue was dissolved in CH2Cl2. It was
washed with water several times and dried over MgSO4. The
concentrated crude product was purified by silica gel column
chromatography using EtOAc–hexane (2 : 1) as eluent. The best
fractions were collected and concentrated. The residue was
dissolved in CH2Cl2 and washed with deionized water several
† The IUPAC name for 2-picolyl chloride hydrochloride is 2-
(chloromethyl)pyridine hydrochloride.
920
J. Chem. Soc., Perkin Trans. 2, 2001, 916–922